Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: With strong cash generation and stable dividends, what are your plans for cash usage going forward? A: Antonio Zamora Galland, Executive Vice President, CFO, and CAO, stated that while significant CapEx is not planned, there are projects for innovation and productivity. The company does not intend to further reduce leverage significantly but will reinvest in the business to accelerate growth.
Q: What is the medium-term plan for dividends from Argentina and margin targets? A: CEO Juan Marco Sparvieri mentioned plans to extract cash from Argentina when possible. The company aims to sustain a 24% EBITDA margin, with reinvestment in the business not affecting this target due to productivity initiatives.
Q: How are you preparing for the high season for Suerox in 2025? A: CEO Juan Marco Sparvieri explained that inventory buildup began in November 2024 to ensure sufficient product availability. Antonio Zamora Galland added that this practice aligns with industry standards to meet peak demand.
Q: Can you provide more details on CapEx plans and potential for increasing dividends? A: Antonio Zamora Galland noted that while major manufacturing CapEx is not needed, there may be investments in logistics and distribution capacity. The focus is on reinvesting excess margins from productivity gains to accelerate growth.
Q: What are your growth expectations for 2025 and 2026? A: CEO Juan Marco Sparvieri indicated that while specific guidance is not yet available, the company expects to accelerate growth faster than in the past, driven by strategic investments in core brands.
Q: Do you foresee any impact from tariffs in the US? A: CEO Juan Marco Sparvieri stated that 80% of products sold in the US are produced domestically, minimizing tariff impact.
Q: What are your plans for growth in the US market? A: CEO Juan Marco Sparvieri highlighted the potential for Suerox to continue expanding in the US, with plans to increase distribution and consumer reach.
Q: Can you provide more details on the Asepxia and Cicatricure relaunches? A: CEO Juan Marco Sparvieri shared that the Asepxia relaunch is underway with new shelf executions, and Cicatricure's new variant, Neurosen, is performing well. Data on Asepxia's performance is forthcoming.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.